Novel Therapies for Treating Familial Hypercholesterolemia

被引：6

作者：

Bandeali, Salman J. ^{[1
]}

Daye, Jad ^{[2
]}

Virani, Salim S. ^{[2
,3
,4
,5
,6
,7
]}

机构：

[1] St Lukes Episcopal Hosp, Texas Heart Inst, Cardiol Sect, Dept Med, Houston, TX 77030 USA

[2] Baylor Coll Med, Dept Med, Houston, TX 77030 USA

[3] Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Hlth Policy Qual & Informat Program, Houston, TX 77030 USA

[4] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX 77030 USA

[5] Houston Methodist DeBakey Heart & Vasc Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX 77030 USA

[6] Michael E DeBakey VA Med Ctr, Cardiol Sect, Houston, TX 77030 USA

[7] Michael E DeBakey VA Med Ctr, Hlth Serv Res & Dev 152, Houston, TX 77030 USA

来源：

CURRENT ATHEROSCLEROSIS REPORTS | 2014年 / 16卷 / 01期

关键词：

Familial hypercholesterolemia; Mipomersen; Proprotein convertase subtilisin/kexin 9 inhibitors; Lomitapide; DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; B SYNTHESIS INHIBITOR; VIVO GENE-THERAPY; TRIGLYCERIDE TRANSFER PROTEIN; PLACEBO-CONTROLLED TRIAL; MONOCLONAL-ANTIBODY; LDL CHOLESTEROL; DOUBLE-BLIND; PLASMA-CHOLESTEROL;

D O I：

10.1007/s11883-013-0382-0

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Familial hypercholesterolemia is an inherited disorder associated with early accelerated atherosclerosis with morbidity and mortality resulting from premature cardiovascular disease. Affected individuals have extreme elevations in low-density lipoprotein cholesterol levels. Patients usually do not achieve target reductions in cholesterol levels with conventional antihyperlipidemic pharmacotherapy. This unmet need has resulted in the recent development and approval of novel therapies targeting different cholesterol pathways. This article briefly summarizes familial hypercholesterolemia and then discusses the newer pharmacotherapies available in the management of familial hypercholesterolemia.

引用

页数：9

共 50 条

[21] Novel Treatments for Familial Hypercholesterolemia: Pharmacogenetics at Work
Marbach, Jeffrey A.
McKeon, Jessica L.
Ross, Joyce L.
Duffy, Danielle
PHARMACOTHERAPY, 2014, 34 (09): : 961 - 972
[22] Lomitapide: a novel drug for homozygous familial hypercholesterolemia
Panno, Maria D.
Cefalu, Angelo B.
Averna, Maurizio R.
CLINICAL LIPIDOLOGY, 2014, 9 (01) : 19 - 32
[23] Characterization of novel mutations in familial hypercholesterolemia.
Schmidt, H
Stuhrmann, M
Dörk, T
Haas, R
Tietge, U
Ebhard, M
Schmidtke, J
Manns, M
GASTROENTEROLOGY, 1998, 114 (04) : A1337 - A1337
[24] A novel soluble chimera for the treatment of familial hypercholesterolemia
Paillard, F
HUMAN GENE THERAPY, 1999, 10 (07) : 1093 - 1094
[25] Homozygous familial hypercholesterolemia: the impact of novel treatments
Kennedy, Cormac
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 31 (08) : 1036 - 1037
[26] PLASMA-EXCHANGE - A NEW METHOD OF TREATING HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
DABELS, J
PREUSSNER, S
BRAUER, P
WILMBUSSE, H
DEUTSCHE GESUNDHEITSWESEN-ZEITSCHRIFT FUR KLINISCHE MEDIZIN, 1982, 37 (04): : 165 - 168
[27] Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)
Maya S. Safarova
Patrick M. Moriarty
Current Atherosclerosis Reports, 2023, 25 : 391 - 404
[28] Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)
Safarova, Maya S.
Moriarty, Patrick M.
CURRENT ATHEROSCLEROSIS REPORTS, 2023, 25 (07) : 391 - 404
[29] Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins
Faiz, Fathimath
Hooper, Amanda J.
van Bockxmeer, Frank M.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2012, 49 (01) : 1 - 17
[30] Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children
Page, Michael M.
Bell, Damon A.
Hooper, Amanda J.
Watts, Gerald F.
Burnett, John R.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 28 (03) : 387 - 403

← 1 2 3 4 5 →